|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Aristarco V, Serrano D, Gandini S,
Johansson H, Macis D, Guerrieri-Gonzaga A, Lazzeroni M, Feroce I,
Pruneri G, Pagani G, et al: A randomized, placebo-controlled, phase
II, presurgical biomarker trial of celecoxib versus exemestane in
postmenopausal breast cancer patients. Cancer Prev Res (Phila).
9:349–356. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Alvarado-Luna G and Morales-Espinosa D:
Treatment for small cell lung cancer, where are we now? - a review.
Transl Lung Cancer Res. 5:26–38. 2016.PubMed/NCBI
|
|
4
|
Rudin CM, Ismaila N, Hann CL, Malhotra N,
Movsas B, Norris K, Pietanza MC, Ramalingam SS, Turrisi AT III and
Giaccone G: Treatment of small-cell lung cancer: American Society
of Clinical Oncology Endorsement of the American College of Chest
Physicians Guideline. J Clin Oncol. 33:4106–4111. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hanagiri T, Oka S, Takenaka S, Baba T,
Yasuda M, Ono K, So T, Uramoto H, Takenoyama M and Yasumoto K:
Results of surgical resection for patients with large cell
carcinoma of the lung. Int J Surg. 8:391–394. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sumi T, Hirai S, Yamaguchi M, Tanaka Y,
Tada M, Yamada G, Hasegawa T, Miyagi Y, Niki T, Watanabe A, et al:
Survivin knockdown induces senescence in TTF 1-expressing,
KRAS-mutant lung adenocarcinomas. Int J Oncol. 53:33–46.
2018.PubMed/NCBI
|
|
7
|
Puglisi F, Aprile G, Bruckbauer M, Barbone
F, Damante G, Guerra S, Beltrami CA and Di Loreto C: Combined
analysis of MIB-1 and thyroid transcription factor-1 predicts
survival in non-small cell lung carcinomas. Cancer Lett.
162:97–103. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hara K, Saito T, Hayashi T, Mitani K,
Takamochi K, Oh S, Suzuki K and Yao T: Inverse correlation between
galectin-4 and TTF-1 in lung adenocarcinoma. Virchows Arch.
471:375–382. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Matzke-Ogi A, Jannasch K, Shatirishvili M,
Fuchs B, Chiblak S, Morton J, Tawk B, Lindner T, Sansom O, Alves F,
et al: Inhibition of tumor growth and metastasis in pancreatic
cancer models by interference with CD44v6 signaling.
Gastroenterology. 150:513–525.e10. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ssadh HA, Spencer PS, Alabdulmenaim W,
Alghamdi R, Madar IH, Miranda-Sayago JM and Fernández N:
Measurements of heterotypic associations between cluster of
differentiation CD74 and CD44 in human breast cancer-derived cells.
Oncotarget. 8:92143–92156. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Okayama H, Kumamoto K, Saitou K, Hayase S,
Kofunato Y, Sato Y, Miyamoto K, Nakamura I, Ohki S, Sekikawa K, et
al: CD44v6, MMP-7 and nuclear Cdx2 are significant biomarkers for
prediction of lymph node metastasis in primary gastric cancer.
Oncol Rep. 22:745–755. 2009.PubMed/NCBI
|
|
12
|
Ekici S, Cerwinka WH, Duncan R, Gomez P,
Civantos F, Soloway MS and Lokeshwar VB: Comparison of the
prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1),
CD44v6 and microvessel density for prostate cancer. Int J Cancer.
112:121–129. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen JQ, Zhan WH, He YL, Peng JS, Wang JP,
Cai SR and Ma JP: Expression of heparanase gene, CD44v6, MMP-7 and
nm23 protein and their relationship with the invasion and
metastasis of gastric carcinomas. World J Gastroenterol.
10:776–782. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu YJ, Yan PS, Li J and Jia JF:
Expression and significance of CD44s, CD44v6, and nm23 mRNA in
human cancer. World J Gastroenterol. 11:6601–6606. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Z, von Au A, Schnölzer M, Hackert T
and Zöller M: CD44v6-competent tumor exosomes promote motility,
invasion and cancer-initiating cell marker expression in pancreatic
and colorectal cancer cells. Oncotarget. 7:55409–55436.
2016.PubMed/NCBI
|
|
16
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hori M, Tanaka H, Wakai K, Sasazuki S and
Katanoda K: Secondhand smoke exposure and risk of lung cancer in
Japan: A systematic review and meta-analysis of epidemiologic
studies. Jpn J Clin Oncol. 46:942–951. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tanaka Y, Yamaguchi M, Hirai S, Sumi T,
Tada M, Saito A, Chiba H, Kojima T, Watanabe A, Takahashi H, et al:
Characterization of distal airway stem-like cells expressing
N-terminally truncated p63 and thyroid transcription factor-1 in
the human lung. Exp Cell Res. 372:141–149. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ma Y, Fan M, Dai L, Kang X, Liu Y, Sun Y,
Yan W, Liang Z, Xiong H and Chen K: The expression of TTF-1 and
Napsin A in early-stage lung adenocarcinoma correlates with the
results of surgical treatment. Tumour Biol. 36:8085–8092. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu Q and Stamenkovic I: Localization of
matrix metalloproteinase 9 to the cell surface provides a mechanism
for CD44-mediated tumor invasion. Genes Dev. 13:35–48. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Amirghofran Z, Jalali SA, Hosseini SV,
Vasei M, Sabayan B and Ghaderi A: Evaluation of CD44 and CD44v6 in
colorectal carcinoma patients: Soluble forms in relation to tumor
tissue expression and metastasis. J Gastrointest Cancer. 39:73–78.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Marzese DM, Liu M, Huynh JL, Hirose H,
Donovan NC, Huynh KT, Kiyohara E, Chong K, Cheng D, Tanaka R, et
al: Brain metastasis is predetermined in early stages of cutaneous
melanoma by CD44v6 expression through epigenetic regulation of the
spliceosome. Pigment Cell Melanoma Res. 28:82–93. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Z, Zhao K, Hackert T and Zöller M:
CD44/CD44v6 a reliable companion in cancer-initiating cell
maintenance and tumor progression. Front Cell Dev Biol. 6:972018.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Perner S, Wagner PL, Soltermann A,
LaFargue C, Tischler V, Weir BA, Weder W, Meyerson M, Giordano TJ,
Moch H, et al: TTF1 expression in non-small cell lung carcinoma:
Association with TTF1 gene amplification and improved survival. J
Pathol. 217:65–72. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tran TA, Kallakury BV, Sheehan CE and Ross
JS: Expression of CD44 standard form and variant isoforms in
non-small cell lung carcinomas. Hum Pathol. 28:809–814. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Situ D, Long H, Lin P, Zhu Z, Wang J,
Zhang X, Xie Z and Rong T: Expression and prognostic relevance of
CD44v6 in stage I non-small cell lung carcinoma. J Cancer Res Clin
Oncol. 136:1213–1219. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shinohara S, Hanagiri T, Taira A, Takenaka
M, Oka S, Chikaishi Y, Uramoto H, So T, Yamada S and Tanaka F:
Immunohistochemical expression and serum levels of CD44 as
prognostic indicators in patients with non-small cell lung cancer.
Oncology. 90:327–338. 2016. View Article : Google Scholar : PubMed/NCBI
|
